β-thalassemia
Conditions
Brief summary
This is an open label study to evaluate the safety and efficacy of β-globin Restored Autologous Hematopoietic Stem Cells in ß-Thalassemia Major Patients
Detailed description
We will recruit ß-thalassaemia major patients and collect their autologous hematopoietic stem cells, which will be modified with the LentiHBBT87Q system to restore β-globin expression. After conditioning, the autologous hematopoietic stem cells with restored β-globin will be reinfused to the patients and followed up for two years to collect data.
Interventions
β-globin-restored autologous hematopoietic stem cells modified with LentiHBBT87Q
Sponsors
Shenzhen Hemogen
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 35 Years
Healthy volunteers
No
Inclusion criteria
1. Aged 18-35 years (inclusive), ICF can be provided by the patient and/or legal guardian; 2. Definitively diagnosed with severe TDT without genotype restriction, and a valid test report can be provided; 3. Average transfusion volume \> 100 mL/kg/year or transfusion frequency \> 8 times/year within 2 years prior to enrollment, or has been definitively diagnosed with TDT; 4. At least 3 months of full volume transfusion (verification of blood transfusion records can be provided) prior to screening, and Hb is maintained at ≥ 9.0 g/dL; 5. Ferritin load \< 3000 μg/L, cardiac and liver iron indicates moderate or lesser iron overload; records of iron chelation treatments within 3 months before screening (including prescription or receipt) can be provided; 6. Acceptable organ functions (including heart, liver, kidney, lung and coagulation functions), stable disease condition, and suitable for busulfan pre-treatment and hematopoietic stem cell (HSC) transplantation as judged by the investigator; 7. Meets follow-up requirements, adheres to treatment arrangements, and is able to return to the hospital regularly to undergo various examinations within 2 years after reinfusion of HGI-001 injection.
Exclusion criteria
1. Patients with fully HLA-matched donors; 2. Received allogeneic transplantation, which needs to be weighed and evaluated by an expert committee; received other gene therapies; 3. Have previously undergone splenectomy; 4. Uncorrected bleeding disorder; 5. Uncontrolled epilepsy and mental illness; 6. Received hydroxyurea, ruxolitinib, decitabine, or cytarabine within 3 months prior to enrollment; 7. Psychoactive substance abuse, drug or alcohol abuse within 6 months prior to enrollment; 8. Patients with pulmonary hypertension who have not been given effective intervention; 9. Persistent toxicity (≥ CTCAE grade 2) induced by previous treatment; 10. Positive for anti-RBC antibodies in antibody screening; 11. Positive for hepatitis B surface antigen (HBsAg) and HBV DNA copy number \> upper limit of normal (ULN) (HBV DNA test not required for patients negative for HBsAg), positive for hepatitis C virus (HCV) antibody, positive human immunodeficiency virus (HIV), or positive for Treponema pallidum antibody (TP-Ab) (subjects who are positive for the antibody due to vaccination can be enrolled). In certain clinical environments/regions, subjects who are positive for other tests can also be excluded from the trial, such as, human lymphocytic virus-1 (HTLV-1) or -2 (HTLV-2), tuberculosis, and toxoplasmosis. 12. Has or has had malignant tumors or myeloproliferative disease or immunodeficiency disease; 13. Immediate family member with or suspected of having a familial cancer (including but not limited to hereditary breast and ovarian cancers, nonpolyposis colorectal cancer, and adenomatous polyposis); 14. Severe bacterial, viral, fungal or parasitic infection; 15. Other illnesses which render the subject unsuitable for participation (e.g., severe liver, kidney or heart disease); Definition of severe liver and kidney disease: a. Aspartate aminotransferase (AST), alanine aminotransferase (ALT), or total bilirubin \> 3 × ULN; b. Liver magnetic resonance imaging (MRI) indicates significant cirrhosis; c. Liver biopsy indicates cirrhosis, severe fibrosis or active hepatitis (liver biopsy is only performed when liver MRI indicates active hepatitis and significant fibrosis without evidence for cirrhosis); d. Creatinine clearance \< 30% of normal; 16. WBC \< 3 × 109/L and/or PLT \< 100 × 109/L; 17. Has diabetes, abnormal thyroid functions or other endocrine disorder; 18. Participated in other interventional clinical studies within 4 weeks before the trial; 19. Poor adherence or other conditions that renders the subject unsuitable for participation as judged by the investigator.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall response rate | 24 months | Percent of patients with average VCN \> 0.1 in peripheral blood mononuclear cells (PBMCs) and average expression of exogenous adult hemoglobin HbAT87Q \> 2.0 g/dL |
| Incidence and severity of AEs | 0-24 months | The number and the percentage of adverse events related to transplantation will be summarized according to NCI CTCAE 5.0 |
| Incidence of SAEs | 0-24 months | The number of SAE related to transplantation will be summarized according to NCI CTCAE 5.0 |
| Transplantation-related fatal and disabling events within day 100 after transplantation | Day 100 | Transplantation-related fatal and disabling events |
| Overall survival rate during the clinical trial | 0-24 months | Number of patients alive through the whole trial will be record |
| HGI-001 injection-related replicating lentivirus test | 0-24 months | The percentage of RCL should be negative in the 24 months after transplant |
| Change from baseline in Clonal variations containing specific viral integration sites | 0-24 months | Evaluation of the percentage of participants without abnormal clonal proliferation and polyclonal engraftment at 6, 12, 18 and 24 months after transplant. More than 1000 VIS retrieved from peripheral blood should be checked. |
| Number of patients with abnormal hematology and bone marrow cytology within 24 months after reinfusion, and percent of patients with abnormal RBC proliferation | 0-24 months | Number of patients with abnormal hematology and bone marrow cytology |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Changes in liver iron load after reinfusion of HGI-001 injection | 0-24 Months | T2 MRI |
| Treatment response rate | 12 Months | Percent of patients with average VCN \> 0.1 in PBMCs and average expression of exogenous adult hemoglobin HbAT87Q \> 2.0 g/dL after reinfusion of HGI-001 injection |
| Changes use of iron chelation medications after reinfusion of HGI-001 injection | 0-24 Months | iron chelation medications |
| Changes in serum ferritin after reinfusion of HGI-001 injection | 0-24 Months | serum ferritin |
| Percent of subjects with successful HSC engraftment | 1 month | Criteria for successful engraftment: Absolute neutrophil count \> 0.5 × 10 9 /L for 3 consecutive days; platelet count is maintained at \> 20 × 10 9 /L for 7 consecutive days without platelet transfusion |
| Change in transfusion volume or frequency | 0-24 Months | Change in average annual transfusion volume or frequency from baseline or change in percentage |
| Transfusion improvement rate | 0-24 Months | Percent of subjects with ≥ 30% decrease in the average annual (0-12 months, 12-24 months) transfusion volume or frequency from baseline after reinfusion of HGI-001 injection |
| Transfusion independence (TI) rate | 0-24 Months | Percent of subjects who do not require transfusion for at least 12 consecutive months after reinfusion of HGI-001 injection and have a weighted average Hb of ≥ 9.0 g/dL |
| Transfusion-free survival | 0-24 Months | the time when a subject meets the TI criteria and maintains transfusion-free survival |
| Changes in VCN and exogenous adult HbAT87Q expression | 0-24 Months | Vector copy number |
| Changes in cardiac iron load after reinfusion of HGI-001 injection | 0-24 Months | T2 MRI |
Countries
China
Contacts
Primary ContactHaigang Sun
Outcome results
None listed